Abstract
Background: Accumulating evidence has supported that long non-coding ribonucleic acids (lncRNAs) could act as essential regulators in cancer immunity. An immune-related lncRNAs (irlncRNAs) risk signature without specific expression value was established to accurately predict prognosis in patients with breast cancer (BRCA).Methods: First, irlncRNAs were identified using co-expression analysis and differential expressed irlncRNAs (DEirlncRNAs) were recognized by “Limma” package. Then, DEirlncRNA pairs were determined using an iteration loop and a 0-or-1 screening matrix. Next, single factor test and Lasso algorithm followed by multivariate Cox regression were employed to establish risk signature. Besides, the Akaike information criterion (AIC) values were calculated to recognize the optimal cut-off point of low- or high-risk groups. Additionally, the potential role of risk score was explored in terms of overall survival, clinical variables, tumor immune microenvironment features, immunotherapeutic targets, and TMB (tumor mutation board) statues.Results: A total of 946 irlncRNAs were determined and 188 DEirlncRNAs were identified. 15 DEirlncRNA pairs were introduced into establishment of prognostic signature, which harbored powerful and independent predictive prognostic ability. Taking advantage of AIC values, risk model was demonstrated to accurately distinguish samples from the viewpoint of clinical outcome, clinicopathological features, infiltrating immune cells, and immunosuppressive biomarkers. Besides, comprehensive prognostic nomogram was constructed to quantitatively estimate risk. Finally, synergistic effect of risk score with TMB value was corroborated.Conclusions: The DEirlncRNA pairs risk signature without specific expression value possessed excellent prognostic performance and may provide direction for immunotherapy in BRCA.